NZ333063A - Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors - Google Patents

Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors

Info

Publication number
NZ333063A
NZ333063A NZ333063A NZ33306397A NZ333063A NZ 333063 A NZ333063 A NZ 333063A NZ 333063 A NZ333063 A NZ 333063A NZ 33306397 A NZ33306397 A NZ 33306397A NZ 333063 A NZ333063 A NZ 333063A
Authority
NZ
New Zealand
Prior art keywords
matrix metalloproteinase
alkyl
metalloproteinase inhibitors
sulfonamide derivatives
dibenzofuran
Prior art date
Application number
NZ333063A
Inventor
Patrick Michael O'brien
Joseph Armand Picard
Drago Robert Sliskovic
Andrew David White
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NZ333063A publication Critical patent/NZ333063A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Use of a compound of formula I wherein: M is a natural (L) alpha amino acid; X is O, S, S(O)n, CH2, CO, or NRQ; RQ is hydrogen, alkyl, or alkyl-phenyl; R is a side chain of a natural alpha amino acid; R1 is alkoxy, hydroxy, or -NHOR5; R2 and R4 are independently hydrogen, alkyl, phenyl -NO2, halogen, -OR5, -CN, -CO2R5, -SO3R5,-CHO, -COR5, -CONR5R6, -(CH2)nNR5R6, -CF3, or -NHCOR5; R5 and R6 are independently hydrogen or alkyl and n is 0 to 2, in the manufacture of a medicament for inhibiting a matrix metalloproteinase.
NZ333063A 1996-09-04 1997-08-22 Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors NZ333063A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2506296P 1996-09-04 1996-09-04
US5571397P 1997-08-07 1997-08-07
PCT/US1997/014859 WO1998009934A1 (en) 1996-09-04 1997-08-22 Matrix metalloproteinase inhibitors and their therapeutic uses

Publications (1)

Publication Number Publication Date
NZ333063A true NZ333063A (en) 2000-12-22

Family

ID=26699216

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ333063A NZ333063A (en) 1996-09-04 1997-08-22 Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors

Country Status (8)

Country Link
EP (1) EP0931045A1 (en)
JP (1) JP2000517341A (en)
KR (1) KR20000068414A (en)
AU (1) AU735013B2 (en)
BR (1) BR9711988A (en)
CA (1) CA2256716A1 (en)
NZ (1) NZ333063A (en)
WO (1) WO1998009934A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514180A (en) 1996-09-04 2002-05-14 ワーナー―ランバート・コンパニー Compounds for inhibiting matrix metalloproteinases and methods thereof
NZ334897A (en) * 1996-12-09 2001-02-23 Warner Lambert Co Medicaments for treating and preventing heart failure and ventricular dilatation
GB9706255D0 (en) * 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
JP2002521328A (en) * 1998-07-21 2002-07-16 ワーナー−ランバート・カンパニー Combination administration of ACAT inhibitor and MMP inhibitor for treatment of atherosclerotic lesions
KR20010072089A (en) 1998-07-30 2001-07-31 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Tricyclic Sulfonamides and their Derivatives as Inhibitors of Matrix Metalloproteinases
AU4229499A (en) * 1998-07-30 2000-02-21 Warner-Lambert Company Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
WO2000015213A1 (en) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure
US6548667B2 (en) 2000-04-07 2003-04-15 Samsung Electronics Co. Ltd. Sulfonamide derivative as a matrix metalloproteinase inhibitor
MXPA01013172A (en) 2001-02-14 2002-08-21 Warner Lambert Co Sulfonamide matrix metalloproteinase inhibitors.
AR035455A1 (en) * 2001-04-23 2004-05-26 Hoffmann La Roche TRICYCLE DERIVATIVES OF ALQUILHIDROXAMATO, PROCESSES FOR THEIR DEVELOPMENT, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THE USE OF SUCH COMPOUNDS IN THE PREPARATION OF MEDICINES
JP2006506379A (en) 2002-10-23 2006-02-23 グレンマーク・ファーマシューティカルズ・リミテッド Novel tricyclic compounds useful for the treatment of inflammatory and allergic diseases: methods for their preparation and pharmaceutical compositions containing them
BRPI0409747A (en) * 2003-04-11 2006-05-09 Glenmark Pharmaceuticals Sa novel heterocyclic compounds useful for treating inflammatory and allergic disorders, processes for their preparation and pharmaceutical compositions containing these
WO2004111044A1 (en) * 2003-06-17 2004-12-23 Glenmark Pharmaceuticals Ltd. Tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation
CA2583497A1 (en) 2004-10-13 2006-04-20 Glenmark Pharmaceuticals S.A. Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide
KR101317119B1 (en) 2004-12-17 2013-10-11 그렌마크 파머수티칼스 에스. 아. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
SI1831227T1 (en) 2004-12-17 2013-09-30 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
MX2009004289A (en) * 2006-10-27 2009-05-05 Wyeth Corp Tricyclic compounds as matrix metalloproteinase inhibitors.
CL2008001257A1 (en) * 2007-05-04 2008-07-04 Wyeth Corp TRICYCLE COMPOUNDS, INHIBITORS OF MARRIAGE METALOPROTEINASES; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS REUMATOID ARTHRITIS, OSTEOARTHRITIS, ATEROSCLEROSIS, LUNG CANCER, AMONG OTHERS.
CN105906665B (en) * 2016-05-16 2017-11-28 中国医学科学院医药生物技术研究所 Carbazole sulfonamide derivative prodrug or its officinal salt and its preparation method and application
CN114981251B (en) * 2020-01-21 2023-11-21 深圳信立泰药业股份有限公司 Dibenzofuran derivative cathepsin K inhibitor and preparation method and medical application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845097A (en) * 1969-09-06 1974-10-29 Ajinomoto Kk N-substituted amino acids and novel ester
NL7013043A (en) * 1969-09-06 1971-03-09
DE2065966C3 (en) * 1969-09-06 1978-11-16 Ajinomoto Co., Inc., Tokio N-fluorenyl-sulfonyl-aminocarboxylic acids and agents containing them
US4097472A (en) * 1974-11-08 1978-06-27 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
EP0183271B1 (en) * 1984-11-30 1990-05-16 Shosuke Okamoto Lysin derivative and proteinase inhibitor
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
AU717570B2 (en) * 1995-06-02 2000-03-30 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
NZ321293A (en) * 1995-11-17 2001-04-27 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases
CZ298814B6 (en) * 1996-01-23 2008-02-13 Shionogi & Co., Ltd. Sulfonated derivatives of amino acids and metalloprotease inhibitors in which said derivatives are comprised

Also Published As

Publication number Publication date
EP0931045A1 (en) 1999-07-28
BR9711988A (en) 1999-08-24
KR20000068414A (en) 2000-11-25
WO1998009934A1 (en) 1998-03-12
JP2000517341A (en) 2000-12-26
AU735013B2 (en) 2001-06-28
AU4159597A (en) 1998-03-26
CA2256716A1 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
NZ333063A (en) Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors
EE03869B1 (en) Sulphinic acid derivatives, their preparation and use
FI971412A0 (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloprotease
HUP9904361A2 (en) Use of isobutylgaba and its derivatives for the treatment of pain
HUP0203939A2 (en) Pharmaceutical compounds and compositions containing them and their use
BR0317149A (en) Methods for Using a Beverage Composition
AU2910600A (en) Phenyl urea and phenyl thiourea derivatives
DK568885D0 (en) SURE INDOLIC COMPOUNDS AND THEIR USE AS ANTIALLERGIC AGENTS
ES2174989T3 (en) PIRIDO (3,2-E) PIRAZINONAS WITH ANTIASMATICS AND PROCEDURE FOR PREPARATION.
HK1028023A1 (en) N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
NZ333064A (en) Subsituted dibenzofurans as inhibitors of matrix metalloproteinases
TR200200263T2 (en) New selective retinoid agonists
ES2173858T3 (en) ANALOGS OF HUPERZINA A.
NZ512851A (en) Derivatives of monosaccharides as cell adhesion inhibitors
BR9806321A (en) Process and composition to inhibit polymerization during anaerobic styrene production.
HUP0102025A2 (en) Derivatives of 1,3,4-oxadiazolone, pharmaceutical compositions containing them and their use
DK1000034T3 (en) Substituted 6-alkylphenanthridines
DE59908967D1 (en) INDOLINE DERIVATIVES AS A LIGHT PROTECTION AGENT
BR9713159A (en) Substantially solid composition, compound, substantially solid salt composition, mixture, and, process for preparing a compound
ATE43588T1 (en) BENZOFURAN DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND ANTI-HYPERTENSIVE AGENTS CONTAINING THEM.
ZA854018B (en) Use of hydroxyindole derivatives in lowering blood pressure
BRPI9703099A (en) carbohydrate derivative, and pharmaceutical composition
SE9701681D0 (en) New compounds
BR9808939A (en) Composition for hair treatment for topical application
ES532056A0 (en) A PROCEDURE FOR PREPARING 5-HALOVINYL-2'-DEOXYURIDINE DERIVATIVES.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)